Publication of a Prospectus
12 June 2019 16:45 BST
Publication of Prospectus
Following a routine technical update of the Company's Euro Medium Term Note ("EMTN") programme established in 2007, the following prospectus has been approved by the UK Listing Authority and is available for viewing:
Base Prospectus for the AstraZeneca PLC U.S. $10,000,000,000 Euro Medium Term Note Programme (the "Prospectus").
The last drawdown under the EMTN programme was in 2016.
To view the full document, please paste the following URL into the address bar of your browser.
A copy of the above Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.
|Gonzalo Viña||+44 203 749 5916|
|Rob Skelding||Oncology||+44 203 749 5821|
|Rebecca Einhorn||Oncology||+1 301 518 4122|
|Matt Kent||BioPharma||+44 203 749 5906|
|Jennifer Hursit||Other||+44 203 749 5762|
|Christina Malmberg Hägerstrand||Sweden||+46 8 552 53 106|
|Michele Meixell||US||+1 302 885 2677|
|Thomas Kudsk Larsen||+44 203 749 5712|
|Henry Wheeler||Oncology||+44 203 749 5797|
|Christer Gruvris||BioPharma (cardiovascular; metabolism)||+44 203 749 5711|
|Nick Stone||BioPharma (respiratory; renal)||+44 203 749 5716|
|Josie Afolabi||Other medicines||+44 203 749 5631|
|Craig Marks||Finance, fixed income||+44 7881 615 764|
|Jennifer Kretzmann||Corporate access, retail investors||+44 203 749 5824|
|US toll-free||+1 866 381 72 77|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.